Moderna stock ‘to jump another 25%’ on positive Covid-19 vaccine data

By Ben Winck, Business Insider KEY POINTS: Goldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed “encouraging” results. Moderna announced Monday that all 45 volunteers in the trial produced antibodies to protect against Covid-19 infection. Shares jumped as much as 39%

Read more